AIMC Topic: Ritonavir

Clear Filters Showing 1 to 6 of 6 articles

Switching to a NRTI-free 2 drug regimen (2DR) -a sub-analysis of the 48 weeks DUALIS study on metabolic and renal changes.

HIV research & clinical practice Mar 2, 2022
Switching from a three-drug regimen (3DR: boosted darunavir [bDRV] and two nucleoside reverse transcriptase inhibitors [NRTIs]) to a two-drug regimen (2DR: bDRV and dolutegravir [DTG]) demonstrated non-inferiority with regard to viral suppression in...
Darunavir Humans Ritonavir HIV Infections Anti-HIV Agents HIV-1
View on PubMed

Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.

The lancet. Gastroenterology & hepatology Jun 16, 2016
BACKGROUND: In Egypt, chronic hepatitis C virus (HCV) infection occurs in around 10% of the population (about 8 million individuals), and is a leading cause of liver cirrhosis, hepatocellular carcinoma, and mortality. Although HCV genotype 4 constitu...
Treatment Outcome Humans Follow-Up Studies Female Cyclopropanes Aged Macrocyclic Compounds Drug Administration Schedule Egypt Aged, 80 and over Ribavirin Anilides Sulfonamides Sustained Virologic Response Adolescent Carbamates Young Adult Hepacivirus Antiviral Agents Lactams, Macrocyclic Adult Administration, Oral Ritonavir Genotype Male Proline Drug Therapy, Combination Liver Cirrhosis Middle Aged Hepatitis C, Chronic Valine
View on PubMed DOI

Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial.

The lancet. Gastroenterology & hepatology Jun 16, 2016
BACKGROUND: Hepatitis C virus (HCV) genotype 4 infection is most commonly reported in sub-Saharan Africa and the Middle East; however, prevalence is increasing worldwide through immigration. HCV genotype 4 accounts for 20% of all infections, but clin...
Ribavirin Sustained Virologic Response Anilides Carbamates Lactams, Macrocyclic Macrocyclic Compounds Sulfonamides Hepacivirus Proline Ritonavir Drug Therapy, Combination Hepatitis C, Chronic Valine Drug Administration Schedule Genotype Treatment Outcome Follow-Up Studies Cyclopropanes Male Middle Aged Adolescent Antiviral Agents Humans Aged, 80 and over Female Young Adult Aged Adult
View on PubMed DOI

Antiviral Effectiveness, Clinical Outcomes, and Artificial Intelligence Imaging Analysis for Hospitalized COVID-19 Patients Receiving Antivirals.

Influenza and other respiratory viruses Sep 1, 2024
INTRODUCTION: There is still a lack of clinical evidence comprehensively evaluating the effectiveness of antiviral treatments for COVID-19 hospitalized patients.
Aged Adult Male Middle Aged Tomography, X-Ray Computed Humans Female Artificial Intelligence SARS-CoV-2 Pandemics Hospitalization COVID-19 Coronavirus Infections COVID-19 Drug Treatment Lung Retrospective Studies Ritonavir Betacoronavirus Antiviral Agents Pneumonia, Viral Treatment Outcome Drug Combinations
View on PubMed DOI

Application of machine intelligence technology in the detection of vaccines and medicines for SARS-CoV-2.

European review for medical and pharmacological sciences Nov 1, 2020
Researchers have found many similarities between the 2003 severe acute respiratory syndrome (SARS) virus and SARS-CoV-19 through existing data that reveal the SARS's cause. Artificial intelligence (AI) learning models can be created to predict drug s...
Humans Artificial Intelligence COVID-19 Vaccines Drug Development Antibodies, Monoclonal, Humanized Drug Combinations Immunosuppressive Agents Machine Learning COVID-19 Deep Learning Antiviral Agents Chloroquine Hydroxychloroquine Adenosine Monophosphate COVID-19 Drug Treatment Drug Repositioning Ribavirin Vitamins Alanine Ascorbic Acid Lopinavir Ritonavir
View on PubMed DOI

[A real-world study of paritaprevir/ritonavir-ombitasvir combined with dasabuvir in the treatment of genotype 1b chronic hepatitis C].

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology Dec 20, 2018
To recognize the efficacy and safety of paritaprevir/ritonavir-ombitasvir combined with dasabuvir (OBV/PTV/RTV+DSV) in the treatment of genotype 1b chronic hepatitis C. Patients with genotype 1b chronic hepatitis C who were admitted to the People's...
Valine Anilides Carbamates Middle Aged Lactams, Macrocyclic Humans China Macrocyclic Compounds Proline Male Treatment Outcome Antiviral Agents Ribavirin Ritonavir Cyclopropanes 2-Naphthylamine Genotype Drug Therapy, Combination Sulfonamides Uracil Hepatitis C, Chronic Hepacivirus
View on PubMed DOI
Popular Topics
Recent Journals